Events
Janssen’s Invokana could become the first diabetes medication to demonstrate reduction in progression to end-stage renal failure in Type 2 diabetes patients with chronic kidney disease.
Cambridge, Mass.-based Alnylam Pharmaceuticals indicated that its ENVISION Phase III trial of givosiran was positive for acute hepatic porphyria (AHP).
Polyphor AG shareholders approved all motions put forward by the Board of Directors to the 22nd Annual General Meeting in Basel.
Developing a Human Factors Validation Plan with Consideration for the Digital Health Marketplace
The shareholders in Recipharm AB (publ), reg. no. 556498-8425, are hereby invited to attend the Annual General Meeting (“AGM”) to be held on Monday 13 May 2019 at 3.00 pm at IVA Konferenscenter, Grev Turegatan 16 in Stockholm, Sweden.
Although it was probably not in serious jeopardy, Bristol-Myers Squibb’s shareholders voted today to approve the acquisition of Celgene Corporation for about $74 billion.
Ultragenyx Pharmaceutical Inc. announced that management and external experts will provide an update to the investment community on the global commercial launch of Crysvita®, the company’s gene therapy programs and platform including manufacturing capabilities, and preclinical data on the next three Investigational New Drug applications the company plans to submit to the U.S. Food and Drug Administration.
Heidelberg Pharma AG reported on the first three months of fiscal year 2019 (1 December 2018 - 28 February 2019) and the Group’s financial figures.
New data shows that patients are extremely satisfied with the medication. Data also showed that through 48 weeks, 84 percent of patients achieved undetectable viral loads, while 8 percent had virologic failures
There are plenty of great scientific research stories out this week. Here’s a look at just a few of them.
PRESS RELEASES